Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray

Abstract

Background/AimsDirect sequencing is the gold standard for the detection of drug-resistance mutations in hepatitis B virus (HBV); however, this procedure is time-consuming, labor-intensive, and difficult to adapt to high-throughput screening. In this study, we aimed to develop a dendron-modified DNA microarray for the detection of genotypic resistance mutations and evaluate its efficiency.MethodsThe specificity, sensitivity, and selectivity of dendron-modified slides for the detection of representative drug-resistance mutations were evaluated and compared to those of conventional slides. The diagnostic accuracy was validated using sera obtained from 13 patients who developed viral breakthrough during lamivudine, adefovir, or entecavir therapy and compared with the accuracy of restriction fragment mass polymorphism and direct sequencing data.ResultsThe dendron-modified slides significantly outperformed the conventional microarray slides and were able to detect HBV DNA at a very low level (1 copy/μL). Notably, HBV mutants could be detected in the chronic hepatitis B patient sera without virus purification. The validation of our data revealed that this technique is fully compatible with sequencing data of drug-resistant HBV.ConclusionsWe developed a novel diagnostic technique for the simultaneous detection of several drug-resistance mutations using a dendron-modified DNA microarray. This technique can be directly applied to sera from chronic hepatitis B patients who show resistance to several nucleos(t)ide analogues.

The risk of hepatocellular carcinoma among chronic hepatitis B virus‐infected patients outside current treatment criteria

“…In this study, we used a cut‐off of 20 IU/mL to define undetectable HBV DNA. However, different cut‐offs (e.g., 12 IU/mL, 15 IU/mL or 60 IU/mL) can be used to define undetectable HBV DNA . It is unclear whether patients with extremely low HBV DNA levels by current PCR assays can benefit from antiviral therapy.…”

Towards the Development of a 3-D Biochip for the Detection of Hepatitis C Virus

“…One of the promising bioanalytical tools for rapid and highly sensitive detection of target components in biological fluids is biochip-based techniques [11,12]. To detect the virus infections, including hepatitis B and C, the development of protein [13][14][15][16] and DNA [17,18] biochips has been known. In the case of hepatitis analysis, the dominating biochip technique is represented by protein microarrays, where virus antigens are applied as probes whereas the detecting molecules are antibodies from a blood serum [19][20][21][22].…”

Profiles of mutations in hepatitis B virus surface and polymerase genes isolated from treatment-naïve Nigerians infected with genotype E

“…Mutations in the structural protein which in turn alters the antigenic properties of the virus may be the cause of the escape of detection by routine serological tests. Furthermore, as previously noted, a reduction in the quantity of HBsAg, might be enough for virus assembly but lower than the minimum limits of the sensitivity of standard ELISA tests [14, 47].…”